The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice

Yumiko Imai, Keiji Kuba, Josef M Penninger, Yumiko Imai, Keiji Kuba, Josef M Penninger

Abstract

During several months of 2002, severe acute respiratory syndrome (SARS) caused by SARS-coronavirus (SARS-CoV) spread rapidly from China throughout the world, causing more than 800 deaths due to the development of acute respiratory distress syndrome (ARDS), which is the severe form of acute lung injury (ALI). Interestingly, a novel homologue of angiotensin-converting enzyme, termed angiotensin-converting enzyme 2 (ACE2), has been identified as a receptor for SARS-CoV. Angiotensin-converting enzyme and ACE2 share homology in their catalytic domain and provide different key functions in the renin-angiotensin system (RAS). Angiotensin-converting enzyme cleaves angiotensin I to generate angiotensin II, which is a key effector peptide of the system and exerts multiple biological functions, whereas ACE2 reduces angiotensin II levels. Importantly, our recent studies using ACE2 knockout mice have demonstrated that ACE2 protects murine lungs from ARDS. Furthermore, SARS-CoV infections and the Spike protein of the SARS-CoV reduce ACE2 expression. Notably, injection of SARS-CoV Spike into mice worsens acute lung failure in vivo, which can be attenuated by blocking the renin-angiotensin pathway, suggesting that the activation of the pulmonary RAS influences the pathogenesis of ALI/ARDS and SARS.

Figures

Figure 1
Figure 1
Current view of ACE and ACE2 functions
Angiotensin I serves as a substrate for both ACE and ACE2. Angiotensin II is known to act as a vasoconstrictor in vivo. The function of angiotensin(1–9) is not well understood. Both ACE and ACE2 are involved in the production of the vasodilator peptide angiotensin(1–7).
Figure 2
Figure 2
Schematic diagram of the proposed role of the renin–angiotensin system in development of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS)
Upon insults such as acid aspiration and sepsis, the generation of Ang II from Ang I is mediated by ACE. Angiotensin II contributes to acute lung failure through stimulation of the AT1R, while ACE2 and AT2R negatively regulate this pathway and protect from acute lung failure. However, additional ACE2‐regulated but Ang II‐independent pathways seem to contribute to ALI/ARDS.
Figure 3
Figure 3
Schematic diagram of the role of the renin–angiotensin system in acute lung failure and proposed SARS‐CoV action
In acute lung injury, such as acid aspiration, pneumonia or sepsis, the generation of Ang II from Ang I is enhanced by ACE, and Ang II induces acute lung failure through stimulation of the AT1R, while ACE2 and AT2R negatively regulate this pathway and protect from acute lung failure. In contrast, SARS‐CoV infection is mediated through binding of the SARS Spike protein to ACE2 or liver/lymph node‐specific intercellular adhesion molecule‐3‐grabbing nonintegrin (L‐SIGN) and downregulates the protective molecule ACE2, thus leading to severe lung injury and acute lung failure.

References

    1. Cambien F, Alhenc‐Gelas F, Herbeth B, Andre JL, Rakotovao R, Gonzales MF et al (1988). Familial resemblance of plasma angiotensin‐converting enzyme level: the Nancy Study. Am J Hum Genet 43, 774–780.
    1. Corvol P, Williams TA & Soubrier F (1995). Peptidyl dipeptidase A: angiotensin I‐converting enzyme. Methods Enzymol 248, 283–305.
    1. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE et al (2002). Angiotensin‐converting enzyme 2 is an essential regulator of heart function. Nature 417, 822–828.
    1. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N et al (2000). A novel angiotensin‐converting enzyme‐related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9. Circ Res 87, E1–E9.
    1. Douglas GC, O'Bryan MK, Hedger MP, Lee DK, Yarski MA, Smith AI & Lew RA (2004). The novel angiotensin‐converting enzyme (ACE) homolog, ACE2, is selectively expressed by adult Leydig cells of the testis. Endocrinology 145, 4703–4711.
    1. Ferrario CM (1990). The renin‐angiotensin system: importance in physiology and pathology. J Cardiovasc Pharmacol 15(Suppl. 3), S1–S5.
    1. Fleming I, Kohlstedt K & Busse R (2006). The tissue renin‐angiotensin system and intracellular signalling. Curr Opin Nephrol Hypertens 15, 8–13.
    1. Hogan RJ, Gao G, Rowe T, Bell P, Flieder D, Paragas J et al (2004). Resolution of primary severe acute respiratory syndrome‐associated coronavirus infection requires Stat1. J Virol 78, 11416–11421.
    1. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B et al (2005). Angiotensin‐converting enzyme 2 protects from severe acute lung failure. Nature 436, 112–116.
    1. Jerng JS, Yu CJ, Wang HC, Chen KY, Cheng SL & Yang PC (2006). Polymorphism of the angiotensin‐converting enzyme gene affects the outcome of acute respiratory distress syndrome. Crit Care Med 34, 1001–1006.
    1. Kakar SS, Sellers JC, Devor DC, Musgrove LC & Neill JD (1992). Angiotensin II type‐1 receptor subtype cDNAs: differential tissue expression and hormonal regulation. Biochem Biophys Res Commun 183, 1090–1096.
    1. Kiely DG, Cargill RI, Wheeldon NM, Coutie WJ & Lipworth BJ (1997). Haemodynamic and endocrine effects of type 1 angiotensin II receptor blockade in patients with hypoxaemic cor pulmonale. Cardiovasc Res 33, 201–208.
    1. Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B et al (2005). A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus‐induced lung injury. Nat Med 11, 875–879.
    1. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA et al (2003). Angiotensin‐converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426, 450–454.
    1. Marceau F & Regoli D (2004). Bradykinin receptor ligands: therapeutic perspectives. Nat Rev Drug Discov 3, 845–852.
    1. Marra MA, Jones SJ, Astell CR, Holt RA, Brooks‐Wilson A, Butterfield YS et al (2003). The Genome sequence of the SARS‐associated coronavirus. Science 300, 1399–1404.
    1. Marshall RP, Webb S, Bellingan GJ, Montgomery HE, Chaudhari B, McAnulty RJ et al (2002). Angiotensin converting enzyme insertion/deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome. Am J Respir Crit Care Med 166, 646–650.
    1. Nicholls MG, Richards AM & Agarwal M (1998). The importance of the renin‐angiotensin system in cardiovascular disease. J Hum Hypertens 12, 295–299.
    1. Rigat B, Hubert C, Alhenc‐Gelas F, Cambien F, Corvol P & Soubrier F (1990). An insertion/deletion polymorphism in the angiotensin I‐converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86, 1343–1346.
    1. Rota PA, Oberste MS, Monroe SS, Nix WA, Campagnoli R, Icenogle JP et al (2003). Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300, 1394–1399.
    1. Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M et al (2005). Incidence and outcomes of acute lung injury. N Engl J Med 353, 1685–1693.
    1. Schanstra JP, Marin‐Castano ME, Praddaude F, Tack I, Ader JL, Girolami JP et al (2000). Bradykinin B1 receptor‐mediated changes in renal hemodynamics during endotoxin‐induced inflammation. J Am Soc Nephrol 11, 1208–1215.
    1. Skeggs LT, Dorer FE, Levine M, Lentz KE & Kahn JR (1980). The biochemistry of the renin‐angiotensin system. Adv Exp Med Biol 130, 1–27.
    1. Suzuki Y, Ruiz‐Ortega M, Lorenzo O, Ruperez M, Esteban V & Egido J (2003). Inflammation and angiotensin II. Int J Biochem Cell Biol 35, 881–900.
    1. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G & Turner AJ (2000). A human homolog of angiotensin‐converting enzyme. Cloning and functional expression as a captopril‐insensitive carboxypeptidase. J Biol Chem 275, 33238–33243.
    1. Turner AJ & Hooper NM (2002). The angiotensin‐converting enzyme gene family: genomics and pharmacology. Trends Pharmacol Sci 23, 177–183.
    1. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J et al (2002). Hydrolysis of biological peptides by human angiotensin‐converting enzyme‐related carboxypeptidase. J Biol Chem 277, 14838–14843.
    1. Victorino GP, Newton CR & Curran B (2002). Effect of angiotensin II on microvascular permeability. J Surg Res 104, 77–81.
    1. Ware LB (2006). Pathophysiology of acute lung injury and the acute respiratory distress syndrome. Semin Respir Crit Care Med 27, 337–349.
    1. Warner FJ, Smith AI, Hooper NM & Turner AJ (2004). Angiotensin‐converting enzyme‐2: a molecular and cellular perspective. Cell Mol Life Sci 61, 2704–2713.
    1. Xu ZH, Shimakura K, Yamamoto T, Wang LM & Mineshita S (1998). Pulmonary edema induced by angiotensin I in rats. Jpn J Pharmacol 76, 51–56.
    1. Yamamoto K, Ohishi M, Katsuya T, Ito N, Ikushima M, Kaibe M et al (2006). Deletion of angiotensin‐converting enzyme 2 accelerates pressure overload‐induced cardiac dysfunction by increasing local angiotensin II. Hypertension 47, 718–726.
    1. Yamamoto T, Wang L, Shimakura K, Sanaka M, Koike Y & Mineshita S (1997). Angiotensin II‐induced pulmonary edema in a rabbit model. Jpn J Pharmacol 73, 33–40.
    1. Yang ZY, Kong WP, Huang Y, Roberts A, Murphy BR, Subbarao K & Nabel GJ (2004). A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428, 561–564.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe